PARNAXLAB Intrinsic Value
Valuation
Blended fair value using DCF and peer comparison methods.
PARNAXLAB Intrinsic Value Analysis
The latest available EOD closing price for PARNAXLAB (PARNAXLAB) is ₹115 per share. Understock's estimated intrinsic value is ₹64 per share. This estimate is 44.2% below that price; the page's comparison band labels the shares overvalued.
The displayed estimate uses the available peer-based value of ₹64; a DCF estimate is not currently available. Peer comparison uses 8 matched industry companies and contributing P/E, P/B multiples.
For context, available company data reports P/E of 88.6×. These metrics describe the business and are not separate intrinsic-value estimates.
How Understock Calculates Intrinsic Value
Understock follows the company's stored valuation classification. Where DCF applies, the model discounts projected or normalized cash flows and terminal value using stored assumptions. Peer valuation compares available company multiples with medians from matched industry or sector companies, with a curated peer-group fallback where database matches are unavailable; the contributing multiples and their weights depend on sector rules and available data. For this page, the available displayed estimate comes from peer valuation. DCF and peer estimates can differ because they use different assumptions, financial metrics, and market reference points.
Review this company's DCF valuation · Learn how DCF works · Use the DCF calculator · See PARNAXLAB peer valuation · What intrinsic value means
The intrinsic value shown is an algorithmic estimate based on publicly available financial data — including DCF analysis, peer comparison, and historical financials. It is not a research report, investment advice, or a recommendation to buy, sell, or hold any security. Stock valuations involve uncertainty and may differ significantly from market prices. Please consult a SEBI-registered investment adviser before making any investment decision.
PARNAXLAB Peer Comparison
How this company stacks up against sector peers on valuation and quality metrics.
Healthcare · 8 peers · sector medians shown
| Company | Mkt Cap | P/E | P/B | EV/EBITDA | ROE | Net Margin | Rev CAGR 3y |
|---|---|---|---|---|---|---|---|
PARNAXLAB PARNAXLAB · you | ₹132 Cr | 88.6× | 5.9× | — | 6.7% | 0.3% | — |
| Sector median | — | 39.2× | 4.3× | 26.4× | 9.0% | 0.2% | 9.4% |
| Syncom Formulations (India) Limited SYNCOMF | ₹1,402 Cr | 16.6× | 4.5× | — | 27.2% | 0.2% | — |
| Gujarat Kidney And Super Speciality Limited GKSL | ₹1,266 Cr | 54.7× | 4.3× | 44.8× | 6.1% | 18.9% | — |
| GPT Healthcare Limited GPTHEALTH | ₹1,246 Cr | 30.1× | 4.7× | 13.9× | 15.7% | 8.9% | 9.4% |
| ONE GLOBAL SERVICE PROVIDER LIMITED ONEGLOBAL | ₹1,163 Cr | 15.7× | 63.1× | — | 401.3% | 0.1% | — |
| Laxmi Dental Limited LAXMIDENTL | ₹1,099 Cr | 39.2× | 4.7× | 26.4× | 11.9% | 10.4% | 19.8% |
| Sigachi Industries Limited SIGACHI | ₹1,041 Cr | 40.0× | 2.3× | — | 5.8% | 0.1% | — |
| Health X Platform Limited HEALTHX | ₹954 Cr | 796.5× | 1.5× | — | 0.2% | 0.1% | 8.3% |
| Bharat Parenterals Limited BPLPHARMA | ₹930 Cr | 96.0× | 2.9× | — | 3.0% | 0.1% | — |
PARNAXLAB trades at a premium to sector peers on P/E (88.6× vs median 39.2×). The market is pricing in higher growth — worth verifying whether recent revenue trends support that expectation.
Business quality
Valuation
Returns
Growth
Efficiency
Liquidity & Solvency
Financial health
Piotroski F-Score, Altman Z-Score, and key solvency ratios.
Full financial data
Charts and annual statements for income, balance sheet and cash flow.
Income trend
Revenue, profit and margin trends over time.
Cash flow
Where cash comes from and where it goes.
Balance sheet
Assets show what the company owns. Liabilities show what it owes. Equity is what's left for shareholders.